Updated data from the Phase I Beamion Lung 1 trial of the HER2 tyrosine kinase inhibitor (TKI), BI 1810631, as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations

被引：0
|
作者：
Heymach, John
Opdam, Frans
Barve, Minal
Tu, Hai-Yan
Wu, Yi-Long
Gibson, Neil
Sadrolhefazi, Behbood
Serra, Josep
Yoh, Kiyotaka
Yamamoto, Noboru
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT203
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT203
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors
    Zhou, Caicun
    Yang, Bo
    Deng, Ting
    Wang, Biyun
    Zhang, Jian
    Sun, Yuping
    Wang, Linlin
    Yang, Hongwei
    Wang, Jingfen
    Li, Wei
    Song, Qi
    Yang, Yuchong
    CANCER RESEARCH, 2024, 84 (07)
  • [42] A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors.
    Plummer, R
    Vidal, L
    Perrett, R
    Shaw, H
    Pilkington, M
    Hanwell, J
    Temple, G
    Fong, P
    Amelsberg, A
    Calvert, H
    de Bono, J
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8990S - 8990S
  • [43] A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours.
    Shaw, H.
    Plummer, R.
    Vidal, L.
    Perrett, R.
    Pilkington, M.
    Temple, G.
    Fong, P.
    Amelsberg, A.
    Calvert, H.
    De Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 127S - 127S
  • [44] A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Cresti, N.
    Jodrell, D.
    Arkenau, T.
    Forster, M.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Plummer, R.
    Spicer, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S160 - S161
  • [45] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Richards, D.
    Braiteh, F.
    Anthony, S.
    Edenfield, W.
    Hellerstedt, B.
    Raju, R.
    Conkling, P.
    McDonagh, C.
    Frye, S.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 170 - 170
  • [46] A phase I trial of the trifunctional anti Her2 x anti CD3 antibody ertumaxomab in patients with advanced solid tumors
    Haense, N.
    Atmaca, A.
    Pauligk, C.
    Steinmetz, K.
    Marme, F.
    Haag, G. M.
    Rieger, M.
    Ottmann, O. G.
    Ruf, P.
    Lindhofer, H.
    Al-Batran, S. -E.
    BMC CANCER, 2016, 16
  • [47] Safety and efficacy of pyrotinib in patients with NSCLC and other advanced solid tumors with activating HER2 alterations: A phase I basket trial.
    Li, Bob T.
    Li, Tianhong
    Johnson, Melissa Lynne
    Waqar, Saiama Naheed
    Zhu, Viola Weijia
    Ou, Sai-Hong Ignatius
    Lin, Jessica Jiyeong
    Wang, Ding
    Shapiro, Geoffrey
    Wang, Judy Sing-Zan
    Liu, Dazhi
    Ye, Yuqing
    Kosar, Hana
    Hee, Angela
    Berk, Greg
    Zhang, Sean
    Wang, Junsheng
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] A phase Ⅰ study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
    Pin Zhang
    Lin Wang
    Yueying Zhen
    Zhihong Wang
    Hesheng Zhang
    Richard Jones
    Binghe Xu
    Chinese Journal of Cancer Research, 2024, 36 (01) : 46 - 54
  • [49] A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
    Chalasani, Pavani
    Marron, Marilyn
    Roe, Denise
    Clarke, Kathryn
    Iannone, Maria
    Livingston, Robert B.
    Shan, Joseph S.
    Stopeck, Alison T.
    CANCER MEDICINE, 2015, 4 (07): : 1051 - 1059
  • [50] Use of BIBW 2992, a novel irreversible EGFR/HER2 tyrosine kinase inhibitor (TKI), to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab
    Hickish, T.
    Wheatley, D.
    Lin, N.
    Carey, L.
    Houston, S.
    Mendelson, D.
    Solca, F.
    Uttenreuther-Fischer, M.
    Jones, H.
    Winer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345